Minerva Neurosciences Inc (NERV)
NERV trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2024-12-31, https://www.sec.gov/Archives/edgar/data/1598646/000095017025026055/0000950170-25-026055-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2024-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | NERV on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2014 |
| SEC CIK | 0001598646 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | MA |
Financials · 2024
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | $1.4M |
| Operating income | -$21.8M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $21.4M |
| Total assets | $37.1M |
| P/E (computed) | 76.2× |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-06 |
| Cash and burn | $20.2M cash; operating cash flow -$7.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 49,835,241 (2026-11-03); 6,993,406 a year earlier; 6,993,406 three years earlier. | Cover page 2026-11-03 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-05-27 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-13 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | $100.7M | -$8.1M | $20.2M | No debt tags | Needs four quarters | 10-Q 2026-11-06 |
| Q2 2026 2026-06-30 | Not filed | $17.5M | -$13.3M | $24.7M | No debt tags | Needs four quarters | 10-Q 2026-11-06 |
| Q1 2026 2026-03-31 | Not filed | -$125.4M | -$5.4M | $32.7M | No debt tags | Needs four quarters | 10-Q 2026-11-06 |
| Q4 2025 2025-12-31 | Not filed | -$283.7M | -$4.5M | $82.3M | No debt tags | Needs four quarters | 10-K 2026-03-11 |
| Q3 2025 2025-09-30 | Not filed | -$2.7M | -$2.9M | $12.3M | No debt tags | Needs four quarters | 10-Q 2026-11-06 |
| Q2 2025 2025-06-30 | Not filed | -$3.3M | -$2.0M | $15.2M | No debt tags | Needs four quarters | 10-Q 2026-11-06 |
| Q1 2025 2025-03-31 | Not filed | -$3.8M | -$4.1M | $17.3M | No debt tags | Needs four quarters | 10-Q 2026-11-06 |
| Q4 2024 2024-12-31 | Not filed | -$4.3M | -$5.2M | $21.4M | No debt tags | $0 | 10-K 2026-03-11 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-05-27 |
| Latest annual report | 10-K | 2026-03-11 |
| Latest quarterly / interim | 10-Q | 2026-11-06 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEFA14A | 2026-04-23 |
Source: SEC EDGAR submissions feed, 650 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -5.0% |
| 1 month | -8.5% |
| 3 months | -41.3% |
| Year to date | -42.8% |
| 1 year | -40.3% |
| From 52-week high | -71.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| OKUR | OnKure Therapeutics Inc. | $2.75 | +4.56% | $111.4M |
| CATX | Perspective Therapeutics Inc. | $0.9238 | -2.05% | $111.6M |
| FHTX | Foghorn Therapeutics Inc. | $1.79 | -13.53% | $107.3M |
| BGM | BGM Group Ltd. | $8.01 | +1.71% | $107.0M |
| PDSB | PDS Biotechnology Corporation | $0.9241 | +5.90% | $113.4M |
| ADAG | Adagene Inc. | $1.60 | -6.43% | $105.7M |
| IMUX | Immunic Inc. | $7.23 | -3.86% | $114.8M |
| CLLS | Cellectis S.A. | $1.04 | -11.86% | $104.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier